-
公开(公告)号：US06936584B1
公开(公告)日：2005-08-30
申请号：US09622104
申请日：1999-02-05
IPC分类号： A61K38/00 , C07K14/575 , A61K37/02 , C07K7/10
CPC分类号： C07K14/575 , A61K38/00 , Y10S514/866
摘要： Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.
摘要翻译： 公开了抑制胰岛淀粉多胺的某些活性但也用作其他胰淀素活性的胰岛淀粉样多肽激动剂的化合物。 这些化合物可用于治疗哺乳动物的燃料代谢紊乱，包括但不限于糖尿病，包括I型糖尿病和II型糖尿病，葡萄糖耐量降低，胰岛素抵抗和X综合症。本发明还涉及 治疗I型糖尿病，有利地调节胃肠蠕动，治疗葡萄糖耐量降低，治疗餐后高血糖症，治疗肥胖症和治疗Syndromne X，包括施用治疗有效量的某些化合物，如本文所述。
-
公开(公告)号：US07442680B2
公开(公告)日：2008-10-28
申请号：US10656093
申请日：2003-09-05
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US06703359B1
公开(公告)日：2004-03-09
申请号：US09622105
申请日：2000-09-22
IPC分类号： A01N3718
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US5625032A
公开(公告)日：1997-04-29
申请号：US96172
申请日：1993-07-21
申请人： Lori Gaeta , Kevin Beaumont , Kathryn Prickett
发明人： Lori Gaeta , Kevin Beaumont , Kathryn Prickett
IPC分类号： A61K38/00 , C07K14/575 , A61K38/16 , C07K14/00
CPC分类号： C07K14/575 , A61K38/00
摘要： Peptides that inhibit amylin activity and that exhibit selectivity for amylin receptors relative to calcitonin and CGRP receptors are provided. These peptides may be used in the treatment of conditions where it is of benefit to reduce amylin activity, including the treatment of Type 2 diabetes mellitus, impaired glucose tolerance, obesity, insulin resistance and hypertension.
摘要翻译： 提供了抑制胰岛淀粉样多肽活性并相对于降钙素和CGRP受体显示对胰岛淀粉样多肽受体的选择性的肽。 这些肽可用于治疗有利于减少胰岛淀粉样多肽活性的病症，包括治疗2型糖尿病，葡萄糖耐量降低，肥胖，胰岛素抵抗和高血压。
-
公开(公告)号：US20110195904A1
公开(公告)日：2011-08-11
申请号：US13080051
申请日：2011-04-05
CPC分类号： G09G3/3233 , G09G2300/0452 , G09G2300/0465 , G09G2300/0804 , G09G2300/0819 , G09G2300/0852 , G09G2300/0861 , G09G2310/0235 , G09G2310/0251 , G09G2320/043 , H01L27/3211 , H01L27/3244
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
6.发明申请公开(公告)号：US20060148713A1
公开(公告)日：2006-07-06
申请号：US11368225
申请日：2006-03-03
IPC分类号： A61K38/22
CPC分类号： A61K9/0019 , A61K38/00 , A61K38/22 , A61K38/2207 , A61K38/2264 , A61K38/23 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , C07K14/57563 , Y10S514/866 , A61K2300/00
摘要： Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了通过减少食物摄入可以缓解的病症或病症的方法，其包括单独施用有效量的毒蜥外泌肽或毒蜥外泌肽激素，或与影响饱腹感的其它化合物或组合物联合施用。 该方法可用于治疗条件或障碍，包括肥胖，II型糖尿病，进食障碍和胰岛素抵抗综合征。 该方法对于降低血浆葡萄糖水平，降低血浆脂质水平，降低心脏风险，降低食欲和降低受试者的体重也是有用的。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US20070066528A1
公开(公告)日：2007-03-22
申请号：US11518574
申请日：2006-09-08
申请人： Nigel Beeley , Kathryn Prickett , Andrew Young , David Hathaway
发明人： Nigel Beeley , Kathryn Prickett , Andrew Young , David Hathaway
IPC分类号： A61K38/22
CPC分类号： A61K45/06 , A61K38/2278 , A61K38/24 , A61K38/26 , A61K2300/00
摘要： The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.
摘要翻译： 本发明涉及治疗多囊卵巢综合征（PCOS）的方法，其包括向患有受试者的患者施用胰高血糖素样肽-1（GLP-1），毒蜥外泌肽及其类似物和激动剂。
-
公开(公告)号：US20060094653A1
公开(公告)日：2006-05-04
申请号：US11055098
申请日：2005-02-11
申请人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett
发明人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： C07K14/575 , A61K38/00 , C07K14/475
摘要： The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.
-
公开(公告)号：US20060074012A1
公开(公告)日：2006-04-06
申请号：US11282085
申请日：2005-11-17
申请人： Richard Hiles , Kathryn Prickett
发明人： Richard Hiles , Kathryn Prickett
CPC分类号： A61K38/2278 , Y10S514/866
摘要： Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.
摘要翻译： 用于治疗妊娠糖尿病的方法包括施用有效量的毒蜥外泌肽或毒蜥外泌肽激素，单独或与降低血糖水平的其它化合物或组合物联合使用。
-
公开(公告)号：US20050215469A1
公开(公告)日：2005-09-29
申请号：US10894999
申请日：2004-07-19
IPC分类号： A61K45/00 , A61K35/56 , A61K38/00 , A61K38/17 , A61K38/22 , A61K38/23 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , C07K14/575
CPC分类号： A61K9/0019 , A61K38/00 , A61K38/22 , A61K38/2207 , A61K38/2264 , A61K38/23 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , C07K14/57563 , Y10S514/866 , A61K2300/00
摘要： Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了通过减少食物摄入可以缓解的病症或病症的方法，其包括单独施用有效量的毒蜥外泌肽或毒蜥外泌肽激素，或与影响饱腹感的其它化合物或组合物联合施用。 该方法可用于治疗条件或障碍，包括肥胖，II型糖尿病，进食障碍和胰岛素抵抗综合征。 该方法对于降低血浆葡萄糖水平，降低血浆脂质水平，降低心脏风险，降低食欲和降低受试者的体重也是有用的。 还公开了用于本发明方法的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.03 秒)
